ACTRN12620001095954招募中2 期
The Candesartan Adjunctive Major Depression Trial - CADET: A double-blind, randomised, placebo-controlled trial to evaluate the effect of candesartan on mood in participants with major depressive disorder
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •I.A DSM-5 diagnosis of current major depressive disorder determined by the SCID-5-RV
- •II.Moderate to severe depression indexed by a MADRS score of greater than or equal to 20. If there is a delay of greater than 7 days between screening and baseline assessments, or baseline assessment and medication commencement, the inclusion scale (MADRS) should be administered again to ensure the participant still meets eligibility criteria;
- •III.Aged 18 years and above;
- •IV.Have the capacity to consent to the study and to follow its instructions and procedures;
- •V.Participants will need to have been on stable pre-existing pharmacological or psychotherapy regimens for two weeks prior to study entry;
- •VI.Be using effective contraception if female, sexually active and of childbearing age,
- •VII.Be able to speak, read, write and understand the English language,
- •VIII.Participants will be required to nominate a current treating physician,
- •IX.Willing to consent to blood collection for safety monitoring. ; I.A DSM-5 diagnosis of current major depressive disorder determined by the SCID-5-RV
- •II.Moderate to severe depression indexed by a MADRS score of greater than or equal to 20. If there is a delay of greater than 7 days between screening and baseline assessments, or baseline assessment and medication commencement, the inclusion scale (MADRS) should be administered again to ensure the participant still meets eligibility criteria;
- •III.Aged 18 years and above;
- •IV.Have the capacity to consent to the study and to follow its instructions and procedures;
- •V.Participants will need to have been on stable pre-existing pharmacological or psychotherapy regimens for two weeks prior to study entry;
- •VI.Be using effective contraception if female, sexually active and of childbearing age,
- •VII.Be able to speak, read, write and understand the English language,
- •VIII.Participants will be required to nominate a current treating physician,
- •IX.Willing to consent to blood collection for safety monitoring.
排除标准
- •I. A diagnosis of bipolar disorder and/or another psychotic disorder and/or current substance use disorder, assessed using the SCID-5-RV;
- •II. Undergoing electroconvulsive therapy (ECT) or transcranial magnetic stimulus (TMS) therapy within one month of randomisation in the study;
- •III. Known or suspected clinically unstable systemic medical disorder, including heart disease especially congestive heart failure, cerebrovascular, liver or kidney disease including renal artery stenosis;
- •IV. Participants on current use of any AT1R blockers or ACE inhibitors medications (such as captopril, enalapril, losartan, irbesartan) will be ineligible, although previous use of these (i.e., cessation at least one month prior to entrance in the study) will not preclude participation;
- •V. Systolic blood pressure less than 110 mmHg at the baseline;
- •VI. Symptoms or measures of postural hypotension (reduction in systolic blood pressure of 20mmHg or more after standing from sitting/lying for at least one minute);
- •VII. Safety blood results not cleared by a Principal Investigator or eGFR less than 30 at the baseline;
- •VIII. Current pregnancy or breastfeeding for females;
- •IX. Current use of medications contraindicated with concurrent use of candesartan: aliskiren, digoxin, spironolactone, diuretics, or daily use of non-steroidal anti-inflammatory drugs (such as ibuprofen or celecoxib; PRN use will be accepted);
- •X. Intolerance or allergy to candesartan or any of the trial preparations;
- •XI. Current enrolment in another psychiatric intervention study;
- •XII. Participants on lithium will be accepted on the study but will require additional monitoring of lithium levels;
- •XIII. Participants with current suicidal ideation with a specific plan, defined as a score of 5 or 6 on the MADRS item 10.; I. A diagnosis of bipolar disorder and/or another psychotic disorder and/or current substance use disorder, assessed using the SCID-5-RV;
- •II. Undergoing electroconvulsive therapy (ECT) or transcranial magnetic stimulus (TMS) therapy within one month of randomisation in the study;
- •III. Known or suspected clinically unstable systemic medical disorder, including heart disease especially congestive heart failure, cerebrovascular, liver or kidney disease including renal artery stenosis;
- •IV. Participants on current use of any AT1R blockers or ACE inhibitors medications (such as captopril, enalapril, losartan, irbesartan) will be ineligible, although previous use of these (i.e., cessation at least one month prior to entrance in the study) will not preclude participation;
- •V. Systolic blood pressure less than 110 mmHg at the baseline;
- •VI. Symptoms or measures of postural hypotension (reduction in systolic blood pressure of 20mmHg or more after standing from sitting/lying for at least one minute);
- •VII. Safety blood results not cleared by a Principal Investigator or eGFR less than 30 at the baseline;
- •VIII. Current pregnancy or breastfeeding for females;
- •IX. Current use of medications contraindicated with concurrent use of candesartan: aliskiren, digoxin, spironolactone, diuretics, or daily use of non-steroidal anti-inflammatory drugs (such as ibuprofen or celecoxib; PRN use will be accepted);
- •X. Intolerance or allergy to candesartan or any of the trial preparations;
- •XI. Current enrolment in another psychiatric intervention study;
- •XII. Participants on lithium will be accepted on the study but will require additional monitoring of lithium levels;
- •XIII. Participants with current suicidal ideation with a specific plan, defined as a score of 5 or 6 on the MADRS item 10.
研究者
相似试验
招募中
2 期
The Candesartan Adjunctive Bipolar Depression Trial - CADET: A double-blind, randomised, placebo-controlled trialBipolar depressionMental Health - DepressionACTRN12620000703909Deakin University240
进行中（未招募）
不适用
Candesartan added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months. - CAN-DHFSymptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patientsMedDRA version: 9.1Level: LLTClassification code 10019279Term: Heart failureMedDRA version: 9.1Level: LLTClassification code 10052337Term: Diastolic dysfunctionEUCTR2007-003070-26-DETakeda Pharma GmbH
招募中
不适用
Trial Examining Methods for Antidepressant Discontinuatiodepressionmajor depressive disorder10027946NL-OMON55952Amsterdam UMC200
招募中
1 期
Trial Examining Methods for Antidepressant DiscontinuatioMedDRA version: 21.1Level: LLTClassification code 10025464Term: Major depressive disorder, single episode in full remissionSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 21.1Level: LLTClassification code 10025455Term: Major depressive disorder, recurrent episode, in full remissionSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: LLTClassification code 10025465Term: Major depressive disorder, single episode, in partial or unspecified remissionSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: LLTClassification code 10025456Term: Major depressive disorder, recurrent episode, in partial or unspecified remissionSystem Organ Class: 10037175 - Psychiatric disordersMajor Depressive DisorderEUCTR2021-006108-34-NLAmsterdamUMC (location VUmc)200
已完成
3 期
A Confirmatory Trial on the Alleviation Depressive state Through the Use of Bergamot Essential Oil Before Sleep and Upon Waking: A Crossover Trialhealthy adultJPRN-UMIN000053520Hoshi University36